Neuroscience
National Survey Reveals Nearly Half of Americans Suffer From Unexplained Pain and Illness
A new national survey shows that 48% of Americans experience unexplained chronic pain or illness, highlighting the urgent need for greater awareness and access to neuroplastic treatments that could transform healthcare outcomes.
Cybin Advances Neuropsychiatry Pipeline with Key Clinical Milestones and Extended IP Protection
Cybin Inc. is progressing multiple late-stage clinical programs for mental health treatments, with upcoming data readouts and regulatory advancements that could significantly impact the neuropsychiatry treatment landscape.
Creative Biolabs Launches Advanced Antibody Tools for Neuroscience Research
Creative Biolabs has developed specialized antibody products targeting key neurological proteins that could accelerate research into neurodegenerative diseases, movement disorders, and synaptic function.
Leading Mental Health Expert to Address Youth Crisis at Biofeedback Conference
Dr. Roseann Capanna-Hodge will present brain-based strategies for addressing the youth mental health crisis at the NRBS 2025 conference, offering practical solutions for clinicians, educators, and parents dealing with rising rates of anxiety and depression.
Alicia Kali Establishes World's First Neuroscience and BioQuantum Engineering Institute to Advance Human Health and AI Performance
Alicia Kali has launched the world's first nonprofit institute dedicated to neuroscience and bioquantum engineering, aiming to unify biological intelligence, regenerative health, and artificial cognition through groundbreaking research.
Creative Biolabs Launches Advanced Neuroscience Platforms to Address Growing Neurodegenerative Disease Research Needs
Creative Biolabs has introduced specialized neuroscience research platforms targeting Alzheimer's and other neurodegenerative diseases, providing critical tools for studying cellular mechanisms in both peripheral and central nervous systems to accelerate drug development and mechanistic studies.
Neuroscience Breakthrough Offers New Hope for Locked-In Syndrome Patients and Consciousness Research
Dr. Berenika Maciejewicz's research provides a new diagnostic framework for detecting consciousness in locked-in syndrome patients, with significant implications for brain-computer interfaces and neurological care.
Cybin Executives to Present at TD Cowen Neuropsychiatry Summit Amid Phase 3 Depression Treatment Development
Cybin Inc. executives will present at the TD Cowen Neuropsychiatry & Epilepsy Summit, highlighting the company's late-stage development of novel mental health treatments including CYB003, which has received FDA Breakthrough Therapy Designation for major depressive disorder.
Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
National Survey Reveals Nearly Half of US Adults Experience Unexplained or Treatment-Resistant Pain and Illness
A groundbreaking national survey to be presented at the Association for the Treatment of Neuroplastic Symptoms conference shows that 40% of Americans seeking medical care have symptoms likely caused by stress-induced neural pathway changes rather than structural issues.
New Research Identifies SOX6 Protein as Potential Key to Myelin Repair in Multiple Sclerosis
Groundbreaking research published in Cell reveals that targeting the SOX6 protein could enable myelin repair in multiple sclerosis patients, potentially opening new therapeutic avenues for the neurodegenerative disease.
Cybin Inc. to Present at H.C. Wainwright Global Investment Conference
Cybin Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its late-stage neuropsychiatry developments including breakthrough therapy-designated treatments for major depressive disorder and generalized anxiety disorder.
Cybin Inc. to Present at Cantor Global Healthcare Conference, Highlighting Progress in Neuropsychiatric Treatments
Cybin Inc.'s participation in the Cantor Global Healthcare Conference underscores the company's advancing clinical programs for mental health disorders, including its Phase 3 CYB003 for major depressive disorder and Phase 2 CYB004 for generalized anxiety disorder, both of which hold significant potential to address unmet medical needs.
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference
Annovis Bio's CEO will present at the H.C. Wainwright conference, highlighting the company's focus on developing innovative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Clene Inc. Advances Neurodegenerative Disease Treatment CNM-Au8® Toward Potential FDA Accelerated Approval
Clene Inc. is progressing its oral treatment CNM-Au8® for ALS and multiple sclerosis through late-stage clinical development, with key FDA meetings and regulatory catalysts potentially accelerating commercialization for patients with limited treatment options.
MyBioSource Launches Validated Anti-CALB2 Antibody for Neuroscience Research
MyBioSource has introduced a validated sheep anti-rat calretinin polyclonal antibody that enables advanced research into calcium signaling, neuroprotection, and neurodegeneration across multiple species.
Cybin Receives Australian Approval for Phase 3 Study of Psychedelic-Based Depression Treatment
Cybin Inc. has secured Australian regulatory approval to conduct its EMBRACE Phase 3 clinical trial of CYB003, a novel deuterated psilocin analog, marking a significant advancement in developing next-generation treatments for major depressive disorder.
NRx Pharmaceuticals' Depression Treatment Receives FDA Fast Track Designation
NRx Pharmaceuticals' NRX-100 received FDA Fast Track designation for treating suicidal ideation, potentially expanding its market to 13 million U.S. adults and offering a novel approach targeting neuroplasticity in depression treatment.
New Podcast Explores Neuroplastic Pain Affecting 1.5 Billion People Worldwide
Dr. David Clarke's podcast 'The Story Behind the Symptoms' addresses the growing epidemic of neuroplastic pain conditions through patient interviews and evidence-based Neuroplastic Recovery Therapy, offering alternatives to traditional medical treatments.
AI-Human Collaboration Pioneers Emotional Brain Shunting Research
A groundbreaking collaboration between human researchers and AI systems from OpenAI and Google DeepMind is developing the Emotional Brain Shunting framework to study how the brain redirects emotional energy, potentially revolutionizing mental health and resilience science.
Everyday Strategies to Enhance Brain Health and Cognitive Function
Exploring simple, effective methods to maintain and improve brain health through mental stimulation, diet, mental wellness, and physical activity.
Clene Inc. to Share Corporate Update at Emerging Growth Conference
Clene Inc. is set to present a corporate update at the Emerging Growth Conference, highlighting its progress in developing treatments for neurodegenerative diseases.
Cybin Inc. Receives EU Approval for Phase 3 MDD Study, Marking a Significant Step in Mental Health Treatment
Cybin Inc. has secured European approval to commence its EMBRACE Phase 3 study for CYB003, a potential breakthrough in treating Major Depressive Disorder, highlighting a pivotal moment in neuropsychiatry.
Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference
Clene Inc. will present its innovative treatments for neurodegenerative diseases at the Canaccord 45th Annual Growth Conference, highlighting potential advancements in ALS and MS therapy.
BTT Brain Wellness Institute Pioneers Non-Invasive Brain Health Solutions
The BTT Brain Wellness Institute, founded by Dr. M. Marc Abreu, introduces innovative, non-invasive treatments to optimize brain function, marking a significant advancement in personalized brain health care.
Clene Inc. Advances Toward FDA Approval for ALS Treatment, Highlighting Market Potential
Clene Inc. is making significant progress toward FDA accelerated approval for its ALS drug CNM-Au8®, targeting a $1.3 billion market by 2034 with a novel approach to neurodegenerative diseases.
University of Sydney Researchers Discover Potential Breakthrough in Parkinson's Treatment
A preclinical study by University of Sydney researchers has successfully reversed Parkinson's-like symptoms in mice by targeting a malfunctioning protein, offering hope for future human treatments.
NeuroEyeCoach Study Highlights Benefits for Vision Rehabilitation in Home and Clinic Settings
A new study on NovaVision's NeuroEyeCoach demonstrates significant improvements in visual search performance for patients, whether used at home or in a clinic, supporting its role in vision rehabilitation.
Oragenics Inc. Raises $16.5 Million to Advance Intranasal Concussion Therapy
Oragenics Inc. has successfully closed a $16.5 million public offering to fund the development of its intranasal therapy for concussions, marking a significant step forward in neurological disorder treatments.
InFlectis BioScience's IFB-088 Shows Promise in ALS Treatment Through Groundbreaking Study
InFlectis BioScience's study on IFB-088 demonstrates potential in addressing TDP-43 proteinopathy, offering hope for ALS patients by improving motor neuron survival and function.